RecruitingNCT06388122

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

Sponsor

Mayo Clinic

Enrollment

100 participants

Start Date

Apr 30, 2024

Study Type

OBSERVATIONAL

Conditions

HER2-negative Breast Cancer

Summary

The purpose of this study is to explore the clinical utility of routinely measuring thymidine kinase activity (TKa) in HR+ metastatic breast cancer patients receiving treatment with any approved endocrine therapy either alone or in combination with any approved CDK4/6 inhibitor.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is an observational study (no experimental treatment) that tracks a blood-based test called DiviTum TKa to see if it can predict how well hormone-receptor-positive (HR+) metastatic breast cancer responds to CDK4/6 inhibitor drugs (like palbociclib, ribociclib, or abemaciclib). **You may be eligible if...** - You are a woman (pre- or post-menopausal) with HR+ metastatic breast cancer - You are starting or already receiving a CDK4/6 inhibitor drug with or without hormone therapy, OR you are starting a hormone therapy alone for metastatic disease **You may NOT be eligible if...** - You are using an experimental/investigational treatment - You have early-stage (not metastatic) breast cancer - You are male - You are being actively treated for another cancer Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.